Gentile, Marino
 Distribuzione geografica
Continente #
NA - Nord America 538
EU - Europa 355
AS - Asia 147
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.046
Nazione #
US - Stati Uniti d'America 534
SE - Svezia 164
IT - Italia 79
SG - Singapore 67
IE - Irlanda 41
CN - Cina 28
ID - Indonesia 23
FR - Francia 18
DE - Germania 17
IN - India 13
GB - Regno Unito 8
RU - Federazione Russa 8
HK - Hong Kong 6
AU - Australia 4
CA - Canada 4
LT - Lituania 4
BE - Belgio 3
CZ - Repubblica Ceca 3
KR - Corea 3
TR - Turchia 3
CH - Svizzera 2
GR - Grecia 2
UA - Ucraina 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
EU - Europa 1
FI - Finlandia 1
IQ - Iraq 1
IR - Iran 1
NL - Olanda 1
PL - Polonia 1
Totale 1.046
Città #
Chandler 183
Singapore 56
New York 38
Ashburn 36
Dublin 33
Jakarta 23
Princeton 21
Milan 18
San Mateo 16
Wilmington 15
Marseille 13
Florence 12
Dearborn 9
Pune 9
Los Angeles 7
Norwalk 7
Trieste 7
Boston 6
Garden City 6
Houston 6
Moscow 6
Beijing 5
Fairfield 5
Redwood City 5
Benalla 4
Bologna 4
Cattolica 4
Hong Kong 4
Redmond 4
Seattle 4
Vicopisano 4
Bremen 3
Brussels 3
Falls Church 3
Fremont 3
Genoa 3
Hefei 3
Izmir 3
Jacksonville 3
London 3
Seoul 3
Toronto 3
Washington 3
Andover 2
Bari 2
Brno 2
Central 2
Chengdu 2
Chicago 2
Frankfurt am Main 2
Oshkosh 2
Rome 2
Tashkent 2
Turin 2
Venice 2
Verona 2
Ann Arbor 1
Asti 1
Atlanta 1
Augusta 1
Berlin 1
Bern 1
Boardman 1
Botzingen 1
Brdo 1
Camden 1
Chongqing 1
Clearwater 1
Ferrara 1
Guidonia Montecelio 1
Gurgaon 1
Helsinki 1
Kish 1
Kunming 1
Lausanne 1
Lincoln 1
Millbury 1
Mountain View 1
Munich 1
Naaldwijk 1
Nanchang 1
Nanjing 1
Naples 1
Ottawa 1
Pomigliano D'arco 1
Riano 1
Saint Petersburg 1
San Francisco 1
Santarcangelo di Romagna 1
Tianjin 1
Vergiate 1
Vienna 1
Woodbridge 1
Zhengzhou 1
Totale 670
Nome #
Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome 90
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 66
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 61
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 58
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 57
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 57
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 54
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 47
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 47
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 46
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 46
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 45
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 44
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 44
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 42
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 41
Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia 41
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 37
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 36
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 34
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 31
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 26
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 22
Totale 1.072
Categoria #
all - tutte 6.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.893


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202022 0 0 0 0 5 6 2 2 3 0 4 0
2020/202128 0 0 0 6 0 0 9 0 1 9 1 2
2021/2022233 5 0 49 32 27 5 2 26 7 7 48 25
2022/2023422 58 67 30 64 18 66 15 25 55 3 12 9
2023/2024243 9 59 11 12 15 59 14 12 1 8 14 29
2024/2025113 9 13 31 19 41 0 0 0 0 0 0 0
Totale 1.072